| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Nov 2025 | 24 Nov 2025 |
| Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at its meeting held on 24.11.2025, has approved the following: Establishment of Corporate Office The Board has approved the setting up of a new Corporate Office of the Company at the following address: 1002 10th Floor, Vikram Tower, Rajendra Place, New Delhi-110060. The Corporate Office will support centralised management, administration, and operational functions of the Company. The Board has authorized Umesh Kumar Director to finalize and execute all necessary documents, including lease agreements and related arrangements, and to oversee the setup and operationalization of the office. Pursuant to Regulation 30 of SEBI(LODR) Regulation 2015 we are hereby inform you that the board of director of the company at its meeting held on 24th November has approved the setting up of a new corporate office of the company at the following address : 1002 10th floor, vikram Tower, Rajendra place new delhi 110060 | ||
| Board Meeting | 14 Nov 2025 | 12 Nov 2025 |
| Quarterly Results; Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve the Un-Audited Financial Results of the Company for the quarter and half year ended on 30th September 2025. Un-audited financial results for the quarter and half year ended as on 30th September, 2025. (As per BSE Announcement dated on: 14.11.2025) | ||
| Board Meeting | 27 Oct 2025 | 27 Oct 2025 |
| Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e Monday 27th October 2025 at the Registered Office of the Company and transacted the following major business | ||
| Board Meeting | 6 Oct 2025 | 6 Oct 2025 |
| Updation Pursuant to Second proviso to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Updation in Corporate Information on BSE Portal. | ||
| Board Meeting | 23 Jul 2025 | 16 Jul 2025 |
| Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2025 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 23rd July 2025 inter alia to consider following business. - 1.) To approve and take on record the Un-Audited Financial Results of the Company for the first quarter ended on 30th June 2025. 2.) Any other matter with the permission of the board which the Board may think fit. Please take the above intimation in your records. Thanking You. Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Wednesday 23rd July 2025 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2025. The board meeting commented at 01:15 PM and concluded at 01:40 PM Please take the above intimation in your records. Thanking You, PFA (As Per BSE Announcement Dated on: 23.07.2025) | ||
| Board Meeting | 23 May 2025 | 12 May 2025 |
| Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve PFA This is to inform you that Outcome of the Board Meeting of the Company held on Friday 23rd May 2025 in accordance with SEBl (Listing Obligations and Disclosures Requirements) Regulations, 2015, has been approved by the Board of Directors of the Company and taken on record inter-alia the following items; 1.) Consideration and Approval of Audited Financial Result for the Year ended 31st March, 2025. 2.) Independent Audit Report in pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 for the F.Y. 31st March, 2025. Further, we hereby declare that the Auditor of the Company has issued the Audit report under the Companies Act, 2013 and financial results as prepared under SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on March 31, 2025 with Unmodified opinion. The board meeting commenced on 05:40 PM and concluded on 06:10 PM. Request you to kindly take on record the same. Thanking You. (As Per BSE Announcement Dated on :23.05.2025) | ||
| Board Meeting | 31 Jan 2025 | 21 Jan 2025 |
| Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements ) Regul ations 2015 we would like to inform you t hat a meeting of the Board of Directors of the Company will be held on Friday 31st January 2025 inter alia to consider following business. - 1.) To approve and take on record the Un-Audited Financial Results of the Company for the quarter ended on 31st December 2024 2.) Any other matter with the permission of the board which the Board may think fit. Please take the above intimation in your records. Thanking You. Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Friday 31st January 2025 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and nine months ended on 31st December 2024. The board meeting commented at 06:25 PM and concluded at 06:45 PM Please take the above intimation in your records. Thanking You, PFA (As per BSE Announcement Dated on 31/01/2025) | ||
| Board Meeting | 22 Jan 2025 | 22 Jan 2025 |
| PFA | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.